Latest News

Listen: Every angle on Biogen’s shocking Alzheimer’s news

What exactly is Biogen doing? When is a press release worth $12 billion? And what should patients make of whiplashing news?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. We’re devoting this entire episode to Biogen’s stunning announcement that aducanumab, its once-discarded treatment for Alzheimer’s disease, is getting a second life. First, we break down the news and its near-term implications. Then, STAT’s Sharon Begley joins us to dissect Biogen’s case and explain how outside experts have reacted. Later, we talk to a patient with Alzheimer’s who was in an aducanumab trial and is now dealing with the roller coaster of news. Finally, STAT’s Matthew Herper dials in to illustrate what’s going on behind the scenes at Biogen and what to watch for next.

Read the rest…

Source link

Related posts

Apple launches virtual health studies aiming to enroll hundreds of thousands of customers


Increasing glutamate release in the brain reduces anxiety in marmosets


Información de actualización sobre el coronavirus de la GSMA


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World